Shandong Xinhua Pharmaceutical Tightens Governance With Revised Nomination Committee Charter

Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an announcement.

Shandong Xinhua Pharmaceutical has updated and adopted, as of 31 December 2025, the terms of reference for its Board-level Nomination Committee, first established in 2002, to align with PRC company law, governance codes for listed companies, and Hong Kong Listing Rules. The revised charter formalises the committee’s composition, requiring four to six directors with at least one of a different gender and at least half being independent non-executive directors, mandates that the committee chair be an independent director appointed by the board, and sets out their responsibilities, eligibility criteria, and tenure. It also creates a dedicated working group led by the deputy general manager for human resources to support the committee’s preparatory and information-gathering work on board and senior management candidates, reinforcing the company’s governance structure and succession planning framework for the benefit of shareholders and other stakeholders.

The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Co., Ltd. is a Chinese pharmaceutical manufacturer listed in Hong Kong, engaged in the production and sale of pharmaceutical products and operating under the regulatory framework for listed companies in the People’s Republic of China and Hong Kong.

Average Trading Volume: 2,147,224

Technical Sentiment Signal: Buy

Current Market Cap: HK$9.88B

See more data about 0719 stock on TipRanks’ Stock Analysis page.